(THNR) Amplify Trust - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • • Health
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.
Additional Sources for THNR ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
THNR ETF Overview
| Market Cap in USD | 3m |
| Category | Health |
| TER | 0.59% |
| IPO / Inception | 2024-05-20 |
THNR ETF Ratings
| Growth Rating | -46.1 |
| Fundamental | - |
| Dividend Rating | 3.76 |
| Rel. Strength | -17.8 |
| Analysts | - |
| Fair Price Momentum | 18.86 USD |
| Fair Price DCF | - |
THNR Dividends
| Dividend Yield 12m | 0.95% |
| Yield on Cost 5y | 0.87% |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 100.0% |
THNR Growth Ratios
| Growth Correlation 3m | -81.8% |
| Growth Correlation 12m | -79.2% |
| Growth Correlation 5y | -79.2% |
| CAGR 5y | -13.18% |
| CAGR/Max DD 5y | -0.41 |
| Sharpe Ratio 12m | -0.14 |
| Alpha | -21.78 |
| Beta | 0.751 |
| Volatility | % |
| Current Volume | 9.6k |
| Average Volume 20d | 1k |
What is the price of THNR stocks?
As of April 30, 2025, the stock is trading at USD 21.84 with a total of 9,590 shares traded.
Over the past week, the price has changed by +5.95%, over one month by +1.41%, over three months by -4.56% and over the past year by -13.18%.
As of April 30, 2025, the stock is trading at USD 21.84 with a total of 9,590 shares traded.
Over the past week, the price has changed by +5.95%, over one month by +1.41%, over three months by -4.56% and over the past year by -13.18%.
Is Amplify Trust a good stock to buy?
Probably not. Based on ValueRay Analyses, Amplify Trust (NYSE ARCA:THNR) is currently (April 2025) not a good stock to buy. It has a ValueRay Growth Rating of -46.09 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of THNR as of April 2025 is 18.86. This means that THNR is currently overvalued and has a potential downside of -13.64%.
Probably not. Based on ValueRay Analyses, Amplify Trust (NYSE ARCA:THNR) is currently (April 2025) not a good stock to buy. It has a ValueRay Growth Rating of -46.09 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of THNR as of April 2025 is 18.86. This means that THNR is currently overvalued and has a potential downside of -13.64%.
Is THNR a buy, sell or hold?
Amplify Trust has no consensus analysts rating.
Amplify Trust has no consensus analysts rating.
What are the forecast for THNR stock price target?
According to ValueRays Forecast Model, THNR Amplify Trust will be worth about 21 in April 2026. The stock is currently trading at 21.84. This means that the stock has a potential downside of -3.66%.
According to ValueRays Forecast Model, THNR Amplify Trust will be worth about 21 in April 2026. The stock is currently trading at 21.84. This means that the stock has a potential downside of -3.66%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 21 | -3.7% |